{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080770","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.887775+00:00","generated_at":"2026-06-13T08:41:21.400960+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share","bullets":["Closed underwritten public offering of 23,000,000 shares at $7.50 per share.","Gross proceeds $172.5M; net proceeds expected ~$161.4M after discounts and expenses.","Proceeds to fund lifileucel commercial launch prep, iCTC manufacturing, and clinical programs.","Full exercise of underwriters' option to purchase an additional 3 million shares.","Goldman Sachs & Co. LLC and Jefferies LLC acted as joint lead book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080770","json":"https://secwatch.observer/filing/0001104659-23-080770.json","markdown":"https://secwatch.observer/filing/0001104659-23-080770.md","text":"https://secwatch.observer/filing/0001104659-23-080770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/0001104659-23-080770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/tm2320915d5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:41:21.400960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}